

Contents

Preface *XVII*

Abbreviations and Glossary *XXI*

Part One History 1

1 Introduction 3

2 The Early Period to 1850 5

2.1 Introduction 5

2.2 Experimental Scientific Findings 8

2.2.1 Alcoholic Fermentation 8

2.2.2 'Unformed, Unorganized Ferments' 11

2.3 Application 12

2.3.1 Education 15

2.4 Theoretical Approaches 16

2.4.1 The School of Vitalism 17

2.4.2 The Chemical School 20

2.4.3 History of Science Approaches: Preparadigmatic Research;
Fermentation – An Epistemic Thing 21
References 24

3 The Period from 1850 to 1890 27

3.1 Introduction 27

3.2 Experimental Findings 27

3.2.1 Fermentation – Definite Results by Pasteur 27

3.2.2 'Unformed, Soluble Ferments' – Enzymatic Reactions 35

3.3 Practical Application, Technical Progress and Institutional
Development 35

3.3.1 Products and Progress in Processes 35

3.3.2 Application Research, Bacteriology, and New Institutions 40

3.4 Theoretical Approaches 41

3.4.1 Fermentation Theory, an Epistemic Thing 41

3.4.2	Pasteur Establishes a New Paradigm	42
3.4.3	The Question of Living and Unformed Ferments (Enzymes), and Explanatory Concepts	45
	References	47
4	The Period from 1890 to 1950	51
4.1	Introduction	51
4.2	Research – Advances in the Basics of Biotechnology: Experimental Findings	51
4.2.1	Biochemistry	51
4.2.2	Microbiology	59
4.2.3	The Case of Penicillin – the Beginning of the Antibiotics Era	62
4.3	Technological Development, Progress and Application	64
4.3.1	Expanding Enzyme Technology	64
4.3.2	Wartime Production, First World War: Acetone, Butanol, Glycerol	65
4.3.3	New Fermentation Products: Citric Acid, Fermented Food, Enzymes; Waste Water Treatment	68
4.3.4	War Requirements of the Second World War: Penicillin Production – A New Quality of Technology	70
4.4	Theoretical Approaches	76
4.4.1	The Biochemical Paradigm, and the New Discipline of Biochemistry	76
4.4.2	Microbiology – Normal, Postparadigmatic Science	81
4.4.3	Influences External to Science: War Requirements – the Case of Penicillin	83
	References	84
5	Outlook, from 1950 Onwards: Biotechnology – Science or What?	89
5.1	Introduction	89
5.2	Traditional Biotechnology and the Dechema Report	90
5.2.1	Traditional Products	90
5.2.2	Political Initiatives: The Dechema Report	90
5.2.3	The Scientific Status of Biotechnology up to the 1970s	92
5.3	The Changing Focus in BT in the USA in the Early 1980s	93
5.3.1	The Role of Politics in the USA: The OTA Study, Promoting New BT	93
5.3.2	New Products and Companies	95
5.4	Conclusions	97
	References	98
Part Two	The New Paradigm Based on Molecular Biology and Genetics	101
6	Broadening of Biotechnology through Understanding Life, Genetics and Evolution	103
	References	105

7	The Beginnings of the New Biotechnology	107
7.1	Introduction	107
7.2	The Beginnings of Evolution Theory and Genetics	109
7.2.1	Robust Cultures barely Addressed in Biotechnology	111
7.3	The Origin of Recombinant DNA Technology	113
7.3.1	The Cradle of Gene Cloning: Bacterial and Bacteriophage Genetics	113
7.3.2	Antibiotic Resistance in Hospitals: Genetic Flux in Plasmids	114
7.3.3	‘Restriction and Modification’: Finding the Enzymatic Tools for DNA Recombination	115
7.3.4	Gel Electrophoresis for DNA Analysis and Isolation of Specific Fragments	116
7.3.5	‘Handling DNA’	118
7.3.6	New Tools to Study Single Molecules	119
7.3.7	The First Recombinant DNA Experiments	120
7.3.8	DNA Sequence and Recognizing Genes and Gene Function	122
7.3.9	Cloning Larger DNA Fragments	122
7.3.10	Further Tools for the Assembly of Physical Genome Maps	123
7.3.11	Uniting Fragment, Sequence and Chromosome Maps	124
7.3.12	Understanding Gene Regulation in Eukaryotes: A Branch of Reverse Genetics	127
7.4	Oligonucleotide Synthesis Leads to Protein Engineering	127
7.4.1	Chemical Synthesis of Macromolecules: Peptides and Oligonucleotides	130
7.4.2	Combining Chemistry and Biology to Develop Novel Pharmaceuticals	133
7.4.3	Biotechnology’s Competitor: Cheaper Chemical Synthesis	133
7.4.4	‘Muteins’ and the Beginning of Protein Engineering	134
7.5	Synthetic DNA, Reverse Transcriptase: Isolating Genes	136
7.5.1	Reverse Genetics: Providing Cheap Renewable Resources for ‘Germ-Free’ Products	139
7.5.2	Gene Cloning contributes to the Discovery of and Characterization of New Viral Pathogens: Risk Prevention for Biotechnological Products	141
7.5.3	1979–1990: A Rapid Advance in Characterizing Viral Agents	141
7.5.4	Sera and Antivirals: Biotechnological Products in their Own Right	142
7.5.5	Gene Cloning and Production of Pure Material to Characterize Activity: ‘second Generation Products’	143
7.5.6	Enzymes for Replacement Therapy	144
7.5.7	The Emergence of the ‘New Biotech’ Industry	145
7.5.8	‘Third Generation’ Products and the ‘Post-Gene Cloning’ Era	146
7.6	Biodiversity and Gene Mining	147
7.6.1	Recognizing Groups within Biological Diversity	147
7.6.2	Knowledge of Microbial Diversity was Limited by the Lack of Pure Cultures	147
7.6.3	How Much Diversity is There?	148

7.6.4	Genetic Diversity can be studied by Sequencing Microbial, Organelle and Viral Genomes	148
7.6.5	Microbial Genome Analysis and Bioinformatics to Identify Druggable Targets	150
7.6.6	Recognizing and Utilizing Useful Functional Diversity	150
7.6.7	Functional Screening of ‘Shotgun’ and Metagenomic Libraries	153
7.6.8	Entire Genome Sequence of Microbes of Special Interest	155
7.6.9	‘Gene Mining’ Commercialization and Terminology	156
7.6.10	Dealing with the Data Flux	158
7.7	Creating New Diversity by Design or Empirically	160
7.7.1	Limitations in Predicting Protein Structure and Function	160
7.7.2	Genetic Recombination to Create New Assortments of Gene Fragments: PCR	161
7.8	‘Genetic Fingerprinting’	161
7.9	Inherited Predisposition to Disease	164
7.9.1	Heritable Factors Affecting Probabilities of Developing Disease: Predisposition	165
7.9.2	Services for Genome Analysis as Part of Personal Medicine	166
	References	166
8	Ethical Aspects Related to Genome Research, and Reproductive Medicine	171
8.1	Negative Public Reaction to Gene Technology	171
8.1.1	Initial Lack of Acceptance for Gene Technology in Europe	173
8.1.2	International Scientists’ Concerns Led to Guidelines for Gene Cloning	174
8.1.3	Towards a Solution: Increase Scientists’ Involvement in Technology Assessment	176
8.2	Ethical Aspects: Animal Cloning and Fertility Research	177
8.2.1	The Origin of Cloning Animals	178
8.2.2	An Example of Cloning in Animal Husbandry	179
	References	179
9	Elucidating Protein Structure: The Beginnings of Rational Protein Design	181
9.1	Cambridge England, the Cradle of Structural Analysis of Macromolecules	181
9.1.1	Using Knowledge of Structure for Protein Design	182
9.2	Redesigning the Protein Core	184
9.3	Redesigning the Protein by Altering Primary Sequence	184
9.3.1	Multimer States	184
9.3.2	Solubility and Stability	184
9.3.3	Selectivity and Potency	185
9.3.4	Consensus or Combinatorial Products of Natural Gene Products	185
9.3.5	Protein Fusions	185

9.3.6	Protein Truncations	185
9.4	Post Translational Modifications	186
9.4.1	Glycosylation	186
9.4.2	PEGylation	187
9.4.3	HESylation: An Alternative to PEGylation	187
9.4.4	An Alternative to Post-Translational Modification?	188
9.5	Total Chemical Synthesis	189
9.6	Validation of Drug Design Based on the known Structure of the Target	190
9.7	General Considerations in Drug Development	191
9.7.1	rDNA Technology: Yields an Altered Drug Development Paradigm	191
9.7.2	Recombinant DNA has Generated Novel Biotech Products over the Last Decade	192
9.7.3	The Complex Factors (ADMET) Important for Pharmaceutical Drug Development	193
9.7.4	The Problem of Antigenicity	193
9.7.5	Improving Drug Screening	193
9.7.6	High Information Preclinical Screening	194
9.7.7	Animal Models	194
9.7.8	Animal Models to Identify Targets for Human Hereditary Disease	194
9.7.9	Biomarkers: The New Buzz Word in Clinical Screening	195
	References	195
10	The Development of Antibodies as Pharmaceutical Products	197
10.1	An Introduction to the Immune System	197
10.2	The Beginnings of Applied Immunology	198
10.2.1	The Origin of Vaccination	198
10.2.2	Pure Culture, the Beginnings of Microbiological Science Leading to Production of Vaccines	199
10.3	Monoclonal Antibodies	199
10.3.1	A Critical Mass of Intellect and Technology Forms the Cradle for Monoclonal Antibodies	199
10.3.2	High Specificity and Sensitivity of Antigen Detection	200
10.3.3	The Antibody Molecule	201
10.3.4	rDNA Monoclonals: Reproducible Tools for the Life Sciences	201
10.3.5	Selection of Antibodies from Combinatorial 'Display' Libraries	201
10.3.6	<i>In Vitro</i> Selection for Novel Monoclonal Antibodies	202
10.3.7	Transgenic Mice with a Human Immunoglobulin System	203
10.3.8	Antibody Classes and Antibody Functionality	203
10.3.9	A Summary of the Cell Biology in the Generation and 'Evolution' of a Natural Antibody	203
10.3.10	Combinatorial Display Mimics Natural Antibody Generation and Maturation	205
10.4	Producing Antibodies via rDNA and Combinatorial Biology	205

10.5	Affinity Enrichment on Surfaces of Immobilized Target Molecules	207
10.5.1	Other 'Display' Scaffolds; Peptides to Knottins	208
10.5.2	Fusion to other Minor Coat Proteins	209
10.5.3	Combinatorial Library Affinity Selection: Alternatives to Phage Display	209
10.5.4	Pros and Cons of Microbial versus Animal Cell Systems for Selection and Production	210
10.6	Mice with Human Antibody Gene Repertoires	211
10.7	Two Severe Setbacks during Clinical Testing	212
10.8	A Survey of Therapeutic Antibodies	218
	References	220
11	Hereditary Disease and Human Genome Analysis	221
11.1	Introduction	221
11.2	Heredity Studies and Family Counselling	221
11.2.1	The Beginnings of the Study of Hereditary Factors: Altered Proteins	222
11.2.2	Predisposition for Disease: Quantitative Traits	223
11.2.3	The Concept of a DNA-based Physical Map of the Entire Human Genome, about 1980	223
11.2.4	Prenatal Diagnosis	224
11.2.5	Pre-implantation Diagnosis	224
11.3	Early Attempts to Analyse the Human Genome	225
11.3.1	Human Geneticists give Meaning to the Physical Map	226
11.3.2	Organizing (and Funding) the Genome Effort	226
11.4	The Personalized Genome and Personal Medicine	226
11.4.1	DNA CHIP Technology and Haplotype Mapping	226
11.4.2	High-throughput Screening	227
11.4.3	Ordered Micro-arrays and DNA-CHIPS	228
11.4.4	Scannable Random Arrays: Basis for a New Generation of DNA Sequencing	229
11.4.5	DNA CHIPS for Pharmacogenetics and Cancer Diagnostics	230
11.4.6	Analysis of Complex Systems in Personal Medicine	233
11.5	Analysing the Effect of the Environment on the Human Genome: Epigenetics	233
	References	234
12	Transgenic Animals and Plants	235
12.1	Introduction	235
12.2	Stem Cells and Gene Targeting	236
12.2.1	Selective Gene Markers for Animal Cells	236
12.2.2	Site-Specific DNA Mutation	237
12.2.3	Microinjection into the Cell Nucleus	238
12.2.4	Altered Embryonic Stem Cells	238

- 12.2.5 Transgenic Animals from Engineered ES Cells Injected Into Early Embryos (Blastula) 239
- 12.2.6 Specific Gene Alterations in Animals 239
- 12.2.7 Study of Gene Functionality in Transgenic Animals with Conditionally Induced Genes 239
- 12.2.8 Multicoloured Fluorescent ‘Tags’ to Analyse Complex Tissue Development 240
- 12.2.9 Transgenic Model Organisms: A Tool for Biotechnological Development 241
- 12.2.10 A New Type of Biotechnology Company Based on Transgenics 242
- 12.2.11 Tackling a New Problem Where Cancer Potential is Sequestered as Stem Cells 242
- 12.2.12 Vertebrate Clones from Somatic Cells: The Origin in Transplantation of the Cell Nucleus 243
- 12.2.13 Advances in Fertility Research 243
- 12.2.14 In Vitro Fertilization and the ‘Test Tube Baby’ 244
- 12.2.15 Prenatal and Pre-implantation Diagnosis 244
- 12.2.16 Animal Clones and Accelerated Breeding 244
- 12.2.17 Creating Totipotent Cells with Somatic Cell Nuclei: The Breakthrough for Transgenic Animal Cloning 245
- References 245

- 13 Extrapolating to the Future 247**
- 13.1 Summary of the Status Quo 247
- 13.1.1 Where are the Novel Tools and Interdisciplinary Studies Taking Us? 247
- 13.1.2 Understanding the Whole 248
- 13.2 Insect Control Through ‘Sterile’ Males (SIT) 248
- 13.3 The Future of Gene Therapy 249
- 13.3.1 Slow Progress of Somatic Cell Gene Therapy 249
- 13.3.2 Germ-Line Therapy 250
- 13.4 Stem Cell Therapy 250
- 13.4.1 An Alternative to Human Embryos as a Source of Pluripotent Stem Cells 250
- 13.4.2 Vectors for Re-programming Somatic Cells to Become Stem Cells 253
- 13.4.3 A Revolution in Regenerative Medicine 254
- 13.5 Flash Sequencing DNA: A Human Genome Sequence in Minutes? 255
- 13.5.1 Another Aspect of Personal Medicine becomes a Reality 256
- 13.5.2 Terrasequencing: Stimulating Development of Biotechnology and Molecular Medicine 257
- 13.6 Systems Biology and Looking for ‘Druggable’ Targets 257
- 13.6.1 Understanding Mechanisms of Action and Finding ‘Druggable’ Targets 257
- 13.6.2 Industrial Acceptance of Systems Biology 258

13.6.3	Estimated Number of Potential ‘Druggable’ Targets	259
13.6.4	Target Modulation rather than ‘On/Off’ Agonist Antagonist Effectors	259
13.7	Synthetic Biology	260
13.7.1	Engineered and Synthetic Organisms	261
13.7.2	Synthetic Genomes and Minimal Organisms	261
13.7.3	Generation of a Bacterium with a Completely Synthetic Genome	262
13.7.4	Organisms with Alternative Genetic Codes	263
13.7.5	Understanding other Structural Complexities in the Cell	263
13.7.6	Gene Mining Meets Synthetic Biology	263
13.7.7	Synthetic Biology: The New Metabolic Engineering	264
13.7.8	RNA Machines: Real Genetic Engineering	264
13.7.9	Summing up Synthetic Biology	266
	References	267

14 Biotechnology and Intellectual Property 269

14.1	Introduction	269
14.2	Patents Ensure Growth and Rapid Dissemination of Knowledge	269
14.3	Owning a Patent does not simply Mean that it can be Implemented: ‘Freedom to Operate’ (FTO)	270
14.3.1	Patent Disputes Drive Licence Exchanges and/or Mergers	270
14.3.2	Critical Timing for Biotech Cooperations	270
14.3.3	Orphan Drugs: Special Status Under Patent Law	271
14.3.4	The Patentability of Inventions Relating to Plants and Animals (Europe)	271
14.3.5	The Patentability of Inventions Relating to Elements Isolated from the Human Body	272
14.4	Life-forms as ‘Novel Subject Matter’ for Patents?	272
14.4.1	General Considerations Relating to Biotechnology Patents	273
14.5	Technology ‘State of the Art’: Precedence/Directives, not Fixed by Law	274
14.5.1	Conflict with Moral Codes	274
14.6	Who can make Decisions about Public Morality?	274
14.7	Biotechnology-orientated Directives Guide Patenting Decisions	275
	References	275

Part Three Application 277

15 Bioprocess Engineering 279

15.1	Introduction	279
15.2	Aspects of Applied Microbiology	280
15.3	Biocatalysis	284
15.4	Biochemical Engineering	287
15.5	Process Sustainability and Ecological Considerations	294
15.6	Biosystems Engineering, including Omics Technologies	296

15.7	Outlook and Perspectives	313
	References	315
16	Industrial Biotechnology	321
16.1	Introduction	321
16.2	General Aspects	323
16.2.1	Raw Materials, Resources	323
16.2.2	Biorefineries	326
16.3	Commodities	328
16.3.1	Biofuels	328
16.3.1.1	Processing	329
16.3.1.2	Future Developments and Challenges	332
16.3.2	Biogas, Energy	334
16.4	Chemicals	336
16.4.1	Bulk Products	336
16.4.1.1	Amino Acids	338
16.4.1.2	Organic Acids	339
16.4.1.3	Vitamins	341
16.4.2	Biopolymers	341
16.4.3	Fine Chemicals – Biotransformations and Chiral Synthons	343
16.4.3.1	Oxidoreductases	345
16.4.3.2	Transferases	349
16.4.3.3	Hydrolases	349
16.4.3.4	Lyases and Synthetases, Hydratases	350
16.4.3.5	Outlook	350
16.5	Food Processing and Products	351
16.6	Environmental Processes	355
16.6.1	Aerobic Waste Water Treatment	357
16.6.2	Anaerobic Waste Water Treatment	358
16.6.3	Exhaust Gas Purification and Further Techniques	359
16.7	Summary, Trends and Perspectives	362
	References	363
17	Pharmaceutical Biotechnology	373
17.1	Introduction	373
17.2	Drug Targeting, Discovery Strategies and Development	375
17.2.1	Discovery Strategies	375
17.2.2	Approval Procedure	377
17.2.3	The Case of Epothilone – The Story of a Hit	378
17.3	Pharmaceuticals Production	380
17.3.1	Microbial Fermentation	381
17.3.2	Mammalian Cell Culture – Principles	383
17.4	Products, Pharmaceuticals Made by Biotechnology	387
17.4.1	Low Molecular Weight Agents: Antibiotics, Steroid Biotransformation	389

17.4.1.1	Antibiotics	389
17.4.1.2	Steroid Biotransformation	395
17.4.2	Recombinant Proteins	395
17.4.2.1	Blood Factors and Thrombolytics	398
17.4.2.2	Cytokines, Interferons (IFNs) and Interleukins (ILs)	398
17.4.2.3	Insulin	399
17.4.2.4	Additional Recombinant Hormones	400
17.4.2.5	Monoclonal Antibody (mAb)-Based Products	401
17.4.2.6	Vaccines	401
17.4.3	Further Biopharmaceuticals	402
17.5	Medicinal Techniques, Diagnostics	403
17.5.1	Data Banks, Collections	403
17.5.2	Diagnostic Enzymes and Antibodies	404
17.5.3	Pharmacokinetics, Controlled Release and Drug Targeting	404
17.6	Business: Companies and Economic Aspects	406
17.6.1	General Overview	406
17.6.2	Companies	407
17.6.3	Mergers, Acquisitions, Alliances and Cooperation	409
17.6.4	Conclusions and Future Prospects	411
	References	412

18 Plant Biotechnology 419

18.1	Introduction	419
18.2	Political, Ethical and Biosafety Aspects	420
18.2.1	Political and Ethical Aspects, Patenting	420
18.2.2	Risks and Environmental Aspects	423
18.2.3	Regulations	425
18.2.4	Consumer Acceptance and Public Perception	426
18.3	Research and Development	427
18.3.1	General Principles, Methods	427
18.3.2	Whole Plants and Crop Protection	430
18.3.2.1	Crop Yield and Quality	430
18.3.2.2	Herbicide-Tolerance	434
18.3.2.3	Disease Resistance	436
18.3.3	Products of Primary Metabolism	439
18.3.4	Products of Secondary Metabolism	441
18.4	Application of Modified Plants and Products	444
18.5	Economic Aspects	447
18.6	Summary and Outlook	449
	References	450

Index 455